Recent breakthroughs in immunotherapies such as anti-CD19 CAR-T therapy have demonstrated promising outcomes with a response rate of 85–100% in B-ALL patients with MLL-AF4 (8, 9). Here, KMT2A is linked to precursor B-cell acute lymphoblastic leukemia.